Valneva Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
643
- Stock Symbol
-
VLA
- Investments
-
5
- Share Price
-
$2.84
- (As of Friday Closing)
Valneva General Information
Description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact Information
Website
www.valneva.comCorporate Office
- Îlot Saint-Joseph
- Bureaux Convergence, Bât. A, 12 ter Quai Perrache
- 69002 Lyon
- France
Corporate Office
- Îlot Saint-Joseph
- Bureaux Convergence, Bât. A, 12 ter Quai Perrache
- 69002 Lyon
- France
Valneva Timeline
Valneva Stock Performance
As of 13-Nov-2026, Valneva’s stock price is $2.84. Its current market cap is $540M with 190M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.84 | $2.92 | $2.31 - $6.06 | $540M | 190M | 728K | -$1.05 |
Valneva Financials Summary
As of 30-Jun-2026, Valneva has a trailing 12-month revenue of $167M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 607,358 | 813,081 | 412,083 | 750,637 |
| Revenue | 166,739 | 197,015 | 183,500 | 166,328 |
| EBITDA | (137,565) | (58,965) | 32,162 | (64,607) |
| Net Income | (183,902) | (129,937) | (13,252) | (109,754) |
| Total Assets | 443,364 | 468,480 | 520,319 | 508,552 |
| Total Debt | 240,058 | 243,437 | 225,089 | 230,825 |
Valneva Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Valneva Comparisons
Industry
Financing
Details
Valneva Competitors (70)
One of Valneva’s 70 competitors is Dynavax Technologies, a Formerly VC-backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
| Novavax | Corporation | Gaithersburg, MD | ||||
| Sinovac Biotech | Corporation | Beijing, China | ||||
| CanSino Biologics | Formerly VC-backed | Tianjin, China | ||||
| Agenus | Formerly VC-backed | Lexington, MA |
Valneva Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Valneva Patents
Valneva Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026052881-A1 | Chikungunya virus vaccine multidose formulation and use thereof in outbreaks | Pending | 09-Sep-2024 | ||
| WO-2026052882-A1 | Yellow fever virus (yfv) compositions and production thereof | Pending | 09-Sep-2024 | ||
| WO-2025099278-A2 | Immunogenic zika virus compositions and uses thereof | Inactive | 08-Nov-2023 | ||
| WO-2025099278-A3 | Immunogenic zika virus compositions and uses thereof | Inactive | 08-Nov-2023 | ||
| EP-4676524-A1 | Immunogenic chikungunya compositions for administration to immunocompromised patients | Pending | 08-Mar-2023 | A61K39/12 |
Valneva Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Valneva Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Valneva Investments & Acquisitions (5)
Valneva’s most recent deal was a Corporate Asset Purchase with Valneva (Office Building in Vienna, Austria) for . The deal was made on 31-Oct-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Valneva (Office Building in Vienna, Austria) | 31-Oct-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Crucell Sweden | 09-Feb-2015 | Merger/Acquisition | Pharmaceuticals | ||
| BliNK Biomedical | 11-Dec-2014 | Early Stage VC | Biotechnology | ||
| Intercell | 16-Dec-2012 | Merger/Acquisition | Biotechnology | ||
| Humalys | 01-Jan-2010 | Merger/Acquisition | Biotechnology |
Valneva ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.6 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Valneva FAQs
-
When was Valneva founded?
Valneva was founded in 1999.
-
Where is Valneva headquartered?
Valneva is headquartered in Lyon, France.
-
What is the size of Valneva?
Valneva has 643 total employees.
-
What industry is Valneva in?
Valneva’s primary industry is Biotechnology.
-
Is Valneva a private or public company?
Valneva is a Public company.
-
What is Valneva’s stock symbol?
The ticker symbol for Valneva is VLA.
-
What is the current stock price of Valneva?
As of 13-Nov-2026 the stock price of Valneva is $2.84.
-
What is the current market cap of Valneva?
The current market capitalization of Valneva is $540M.
-
What is Valneva’s current revenue?
The trailing twelve month revenue for Valneva is $167M.
-
Who are Valneva’s competitors?
Dynavax Technologies, Novavax, Sinovac Biotech, CanSino Biologics, and Agenus are some of the 70 competitors of Valneva.
-
What is Valneva’s annual earnings per share (EPS)?
Valneva’s EPS for 12 months was -$1.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
